Clearside Biomedical, Inc. (CLSD)
Automate Your Wheel Strategy on CLSD
With Tiblio's Option Bot, you can configure your own wheel strategy including CLSD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLSD
- Rev/Share 0.0186
- Book/Share -0.5968
- PB -1.3588
- Debt/Equity -0.0135
- CurrentRatio 3.1852
- ROIC -1.7622
- MktCap 63021594.0
- FreeCF/Share -0.3068
- PFCF -2.6707
- PE -2.0247
- Debt/Assets 0.0315
- DivYield 0
- ROE 0.8336
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CLSD | Chardan Capital Markets | -- | Buy | -- | $6 | Aug. 21, 2024 |
News
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m.
Read More
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases
Read More
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.
Read More
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET.
Read More
About Clearside Biomedical, Inc. (CLSD)
- IPO Date 2016-06-02
- Website https://www.clearsidebio.com
- Industry Biotechnology
- CEO George M. Lasezkay Pharm.D., Pharma.D.
- Employees 32